Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,186 shares of the company’s stock, valued at approximately $169,000. Other hedge […]
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price […]